论文部分内容阅读
目的研究利拉鲁肽对2型糖尿病患者血糖和胰岛功能的影响。方法将60例2型糖尿病患者随机分为治疗组及对照组,各30例,治疗组及对照组在原治疗不变的基础上分别加用利拉鲁肽及地特胰岛素。于治疗12、24周时观察两组的糖化血红蛋白(HbA1c)、C肽、胰岛素、血脂、高敏C反应蛋白(hs-CRP)及尿微量白蛋白(MAU)的变化。结果治疗12、24周时,两组HbA1c、FPG、2hPG与治疗前相比均明显降低(P<0.05);治疗12周时治疗组TC、TG及hs-CRP较治疗前均有下降(P<0.05),治疗24周时C肽及胰岛素水平较治疗前均明显上升(P<0.05),体质量指数(BMI)及hs-CRP均明显下降(P<0.05);治疗12、24周时对照组C肽、胰岛素、TC、TG、hs-CRP、MAU及BMI均无显著变化(P>0.05)。结论利拉鲁肽能有效控制2型糖尿病患者的血糖,明显改善胰岛功能,减轻患者体重。
Objective To investigate the effects of liraglutide on blood glucose and pancreatic islet function in type 2 diabetic patients. Methods Sixty patients with type 2 diabetes were randomly divided into treatment group and control group, with 30 cases in each. The treatment group and the control group were treated with liraglutide and insulin detemir respectively on the basis of the same treatment. The changes of HbA1c, C-peptide, insulin, blood lipid, hs-CRP and MAU in both groups were observed at 12 and 24 weeks after treatment. Results At 12 and 24 weeks, the levels of HbA1c, FPG and 2hPG in both groups were significantly lower than those before treatment (P <0.05), and the levels of TC, TG and hs-CRP in treatment group were decreased at 12 weeks (P <0.05). After 24 weeks treatment, the C-peptide and insulin levels were significantly increased (P <0.05), BMI and hs-CRP were significantly decreased (P <0.05) There was no significant change in C peptide, insulin, TC, TG, hs-CRP, MAU and BMI in the control group (P> 0.05). Conclusion Liraglutide can effectively control the blood sugar in patients with type 2 diabetes mellitus, significantly improve pancreatic islet function and reduce body weight.